Literature DB >> 21532505

Comprehensive analysis of epidermal growth factor receptor gene status in lung adenocarcinoma.

Chenguang Li1, Yihua Sun, Zhaoyuan Fang, Xiangkun Han, Rong Fang, Yang Zhang, Yunjian Pan, Wenjing Zhang, Yan Ren, Hongbin Ji, Haiquan Chen.   

Abstract

INTRODUCTION: The epidermal growth factor receptor (EGFR) gene status including tyrosine kinase domain somatic mutations, increased copy number, and protein overexpression are reported to be associated with response to EGFR tyrosine kinase inhibitors in patients with non-small cell lung cancer. The purpose of this study was to elucidate the prevalence of activated EGFR gene and the association between mutation, copy number, and protein overexpression. PATIENTS AND METHODS: In a cohort of consecutive patients with lung adenocarcinoma, polymerase chain reaction and direct sequencing (n = 89) were conducted through exons 18 to 21. Fluorescence in situ hybridization (FISH) (n = 89) and single-nucleotide polymorphism (SNP) array 6.0 (n = 77) were used to detect the gene copy number. The protein expression of EGFR was detected by standard immunohistochemistry (IHC) (n = 89).
RESULTS: Fifty-nine (66.3%) patients harbored somatic mutations of EGFR in tyrosine kinase domain, 55.1% were positive by IHC and 44.9% were positive by FISH, and 66.2% showed gain of copy number according to SNP array 6.0. EGFR somatic mutations are more common in women, never smokers, and tumors with better differentiation. Increased copy number detected by both FISH and SNP array 6.0 analysis is significantly correlated with mutations of EGFR.
CONCLUSIONS: The EGFR somatic mutation rate is significantly higher in Chinese patients with lung adenocarcinoma than western countries. Nevertheless, we found comparable FISH and IHC-positive rates between different ethnics. Considering that FISH may be affected by tumor heterogeneity and other factors, SNP array 6.0 analysis is a good alternative method to detect EGFR copy number variations.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21532505     DOI: 10.1097/JTO.0b013e318215a4f2

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  4 in total

1.  Erlotinib with pemetrexed/cisplatin for patients with EGFR wild-type lung adenocarcinoma with brain metastases.

Authors:  Yalei Zhang; Haihong Yang; Xinyun Yang; Qiuhua Deng; Meilin Zhao; Xin Xu; Jianxing He
Journal:  Mol Clin Oncol       Date:  2014-02-11

2.  EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII).

Authors:  Anita Midha; Simon Dearden; Rose McCormack
Journal:  Am J Cancer Res       Date:  2015-08-15       Impact factor: 6.166

3.  Lentiviral vector-mediated RBM5 overexpression downregulates EGFR expression in human non-small cell lung cancer cells.

Authors:  Zhenzhong Su; Jinzhi Yin; Lijing Zhao; Ranwei Li; Hong Liang; Jie Zhang; Ke Wang
Journal:  World J Surg Oncol       Date:  2014-12-02       Impact factor: 2.754

4.  Primary concomitant EGFR T790M mutation predicted worse prognosis in non-small cell lung cancer patients.

Authors:  Hang Li; Haichuan Hu; Rui Wang; Yunjian Pan; Lei Wang; Yuan Li; Yang Zhang; Ting Ye; Yiliang Zhang; Bin Li; Lei Shen; Yihua Sun; Haiquan Chen
Journal:  Onco Targets Ther       Date:  2014-04-03       Impact factor: 4.147

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.